Form D · Biotechnology
X4 Pharmaceuticals, Inc
Boston, MA · CIK 0001501697
Offering snapshot reported Aug 25, 2025 · SEC filing
- Reported sold
- $85M Offering amount: $85M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 13, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2025 | Initial | $84,999,985 | No comparison | 18 | SEC filing |
| Jun 1, 2023 | Initial | $65,015,462 | No comparison | 22 | SEC filing |
| Jul 19, 2022 | Initial | $55,749,999 | No comparison | 23 | SEC filing |
| Dec 4, 2017 | Initial | $20,000,000 | No comparison | 1 | SEC filing |
| May 8, 2017 | Initial | $45,539,314 | No comparison | 18 | SEC filing |
| Apr 27, 2016 | Initial | $15,007,220 | No comparison | 10 | SEC filing |
| Dec 30, 2015 | Initial | $4,000,000 | No comparison | 8 | SEC filing |
| Jun 5, 2015 | Amendment | $20,000,000 | $7,000,001vs Aug 11, 2014 | 8 | SEC filing |
| Aug 11, 2014 | Amendment | $12,999,999 | $0vs Aug 13, 2013 | 8 | SEC filing |
| Aug 13, 2013 | Initial | $12,999,999 | No comparison | 8 | SEC filing |
| Feb 7, 2011 | Initial | $9,600,002 | No comparison | 7 | SEC filing |
| Sep 24, 2010 | Initial | $400,002 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $3.3M
- Finders' fees
- $0
- Form D file number
- 021-555727
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| STIFEL, NICOLAUS & COMPANY, INCORPORATED | 793 |
Source: Form D, filed Aug 25, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jan Adams | Director |
| William Aliski | Director |
| Errik B Anderson | Director, Executive |
| Christophe Arbet Engels | Executive |
| Mark Baldry | Executive |
| Robert L. Birnbaum | Executive |
| Gary J. Bridger | Director |
| Daniel Burgess | Director |
| Dan Burgess | Director |
| Diego Cadavid | Executive |
| William Clark | Director |
| Adam Craig | Director, Executive |
| Francoise De Craecker | Director |
| Mary Di Biase | Executive |
| Tillman U. Gerngross | Director |
| Carl Gordon | Director |
| Michael Gray | Executive |
| David Kirske | Executive |
| Alison Lawton | Director |
| David Mantus | Executive |
| David Mc Girr | Director |
| Terrance Mc Guire | Director |
| Derek Meisner | Executive |
| Adam Mostafa | Executive |
| Eszter Nagy | Executive |
| Claudio Nessi | Director |
| Paula Ragan | Director, Executive |
| Michael Ross | Director |
| Rene Russo | Director, Executive |
| Amy Schulman | Director |
| Chris Stevens | Executive |
| Murray W. Stewart | Director |
| Arthur Taveras | Executive |
| John Volpone | Executive |
| Michael S. Wyzga | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
61 North Beacon Street 4 Th Floor
Boston, MA, 02134
Boston, MA, 02134